1. The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia
by Amy K. Keating, Jurgen Langenhorst, John E. Wagner, Kristin M. Page, Paul Veys, Robert F. Wynn, Heather Stefanski, Reem Elfeky, Roger Giller, Richard Mitchell, Filippo Milano, Tracey A. O'Brien, Ann Dahlberg, Colleen Delaney, Joanne Kurtzberg, Michael R. Verneris, and Jaap Jan Boelens
BloodAdv
Volume 3(7):
April 9, 2019
© 2019 by The American Society of Hematology

2. Amy K. Keating et al. Blood Adv 2019;3:1118-1128
© 2019 by The American Society of Hematology

3. Hematopoietic engraftment.
Hematopoietic engraftment. Probability and timeline of neutrophil (A) and platelet (B) recovery by stem cell source.
Amy K. Keating et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

4. Kaplan-Meier estimates of posttransplant relapse.
Kaplan-Meier estimates of posttransplant relapse. Incidence of relapse by stem cell source overall.
Amy K. Keating et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

5. Kaplan-Meier estimates of posttransplant outcomes by stem cell source.
Kaplan-Meier estimates of posttransplant outcomes by stem cell source. LFS (A), nonrelapse mortality (B), and OS (C) compared by stem cell source.
Amy K. Keating et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

6. Incidence of GVHD. The incidence of grades II to IV aGVHD (A), incidence of grades III to IV aGVHD (B), and cGVHD (C) compared by stem cell source.
Incidence of GVHD. The incidence of grades II to IV aGVHD (A), incidence of grades III to IV aGVHD (B), and cGVHD (C) compared by stem cell source.
Amy K. Keating et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

7. Composite endpoint cGVHD-LFS.
Composite endpoint cGVHD-LFS. The composite endpoint of cGVHD-LFS.
Amy K. Keating et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology